Live from the JP Morgan Healthcare Conference, James Foster, chairman and CEO at Charles River Laboratories spoke with Mad Money on CNBC. James Foster and Jim Cramer discuss the company’s strategic focus on helping accelerate drug discovery and development.
CHDI Foundation, Inc. has extended its ongoing collaboration with Charles River Laboratories for discovering novel drugs for Huntington's disease for an additional five years.
An approach to consider for detecting latent or endogenous viruses in cell substrates is the use of assays that employ specific chemical compounds to induce virus expression or replication. Following induction, latent and endogenous viruses can then be detected through subsequent assays, such as TEM and QF-PCR testing.
When targeting genes, drug developers may opt for knockdown via CRISPR or silencing via RNAi. These weapons, however, may fit different battle plans.
Don’t fall into the cell line misidentification trap. Authenticate! What you don’t know–or what you refuse to acknowledge–will hurt you.
Today, Charles River Laboratories announced that CHDI Foundation, Inc. has extended its ongoing collaboration for an additional five years. The collaboration, which began in 2005, is focused on discovering novel drugs for Huntington's disease. CHDI has expanded the collaboration with Charles River due to its neuroscience expertise and comprehensive integrated drug discovery capability.
It's no secret that Big Pharma is shedding scientific talent, which is migrating to smaller biotech companies and CROs. As Big Pharma continues to shrink, they will rely even more on those two segments. With more scientific talent in those areas, it can be a win/win situation.
The pharma/CRO relationship can be a complicated one. Each side knows what it wants to gain from the relationship, but those goals or the route to achieve them do not always align. Having a fundamental understanding of what the other side is hoping to accomplish is critical to the relationship developing and maturing in a productive and harmonious manner.
A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.
In this interview, James Foster, chairman and CEO at Charles River Laboratories spoke about the Company's Q3 earnings, the acquisition of ChanTest and why the work we do is so important.